Clinically significant response on positive symptoms at least 50% MS improvement · schizophrenia
Adjunctive lithium + antipsychotics showed no clear difference in clinically significant response on positive symptoms at least 50% MS… compared with placebo/no adjunctive treatment + antipsychotics (low certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · schizophrenia
Lithium as sole treatment showed no clear difference in acceptability of treatment leaving early due to any reason compared with placebo (low certainty).
1 finding from 1 review
Kidney dysfunction outcome not available in any study · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Thyroid dysfunction outcome not available in any study · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
> 50% reduction in depressive symptoms · schizophrenia
Lithium as sole treatment showed no clear difference in clinically significant response on depressive symptoms at least 50%… compared with placebo (low certainty).
1 finding from 1 review
Clinically significant response on manic symptoms at least 50% Bech‐Rafaelsen improvement · schizophrenia
Lithium as sole treatment showed no clear difference in clinically significant response on manic symptoms at least 50%… compared with placebo (low certainty).
1 finding from 1 review
Clinically significant response on positive symptoms at least 50% MS improvement · schizophrenia
Lithium as sole treatment showed no clear difference in clinically significant response on positive symptoms at least 50% MS… compared with placebo (low certainty).
1 finding from 1 review
Kidney dysfunction outcome not available in any study · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Thyroid dysfunction outcome not available in any study · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Clinical efficacy ‐ improvement (> 40%) in ESRS scores from baseline ESRS1 · patients with antipsychotic‐induced tardive dyskinesia
Pyridoxal 5 phosphate (vitamin B6) may leads to higher clinical efficacy ‐ improvement (> 40%) in ESRS scores from baseline… compared with placebo (low certainty).
1 finding from 1 review
Global: Other adverse effects than tardive dyskinesia Self‐report by participants · patients with antipsychotic‐induced tardive dyskinesia
Pyridoxal 5 phosphate (vitamin B6) showed no clear difference in global: Other adverse effects than tardive dyskinesia Self‐report by… compared with placebo (low certainty).
1 finding from 1 review
Global: Discontinuation of Vitamin B6 · patients with antipsychotic‐induced tardive dyskinesia
Pyridoxal 5 phosphate (vitamin B6) showed no clear difference in global: Discontinuation of Vitamin B6 compared with placebo (low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
Pyridoxal 5 phosphate (vitamin B6) showed no clear difference in tardive dyskinesia: Deterioration in tardive dyskinesia symptoms ESRS1 compared with placebo (low certainty).
1 finding from 1 review
General mental state: Positive psychiatric symptom score PANSS5. Scale from: 7 to 49. · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
General mental state: Negative psychiatric symptoms PANSS5. Scale from: 7 to 49. · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether adjunctive carbamazepine + antipsychotics changes acceptability of treatment Leaving the study early due to any reason compared with placebo/no adjunctive treatment + antipsychotics (very low certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
Adjunctive carbamazepine + antipsychotics showed no clear difference in no clinically important change in general mental state Scale used:… compared with placebo/no adjunctive treatment + antipsychotics (low certainty).
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · patients with schizophrenia
1 finding from 1 review
Depressive symptoms · patients with schizophrenia
1 finding from 1 review